Catalyst Pharmaceuticals, Inc. (CPRX)
| Market Cap | 3.60B |
| Revenue (ttm) | 588.99M |
| Net Income (ttm) | 214.33M |
| Shares Out | 122.12M |
| EPS (ttm) | 1.68 |
| PE Ratio | 17.57 |
| Forward PE | 15.70 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,758,007 |
| Open | 29.60 |
| Previous Close | 29.27 |
| Day's Range | 28.61 - 30.25 |
| 52-Week Range | 19.05 - 32.56 |
| Beta | 0.66 |
| Analysts | Strong Buy |
| Price Target | 35.00 (+18.73%) |
| Earnings Date | May 11, 2026 |
About CPRX
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticoste... [Read more]
Financial Performance
In 2025, Catalyst Pharmaceuticals's revenue was $588.99 million, an increase of 19.78% compared to the previous year's $491.73 million. Earnings were $214.33 million, an increase of 30.78%.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for CPRX stock is "Strong Buy" and the 12-month stock price target is $35.0.
News
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
The Company will Host a Conference Call and Webcast on May 12, 2026, at 8:30 AM ET The Company will Host a Conference Call and Webcast on May 12, 2026, at 8:30 AM ET
See How Institutions Boost Catalyst Shares
Shares of Catalyst Pharmaceuticals, Inc. (CPRX) up 148% since 2022's first outlier institutional inflow signal.
Catalyst Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
Revised summary: The company reported strong 2025 results with 20% revenue growth and expects continued momentum in 2026, driven by Firdapse and Agamree. Firdapse benefits from new guidelines and oncology focus, while Agamree's uptake is supported by clinical data. Cash reserves and a share repurchase program provide flexibility for acquisitions and returns.
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and...
Catalyst Pharmaceuticals Earnings Call Transcript: Q4 2025
Record 2025 revenues of $589M (up 19.8% YoY) driven by Firdapse and AGAMREE, with strong net income growth and robust cash position. 2026 guidance projects continued double-digit growth, supported by expanded patient identification and market penetration initiatives.
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FI...
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
CORAL GABLES, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ET
Catalyst Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted a rare disease-focused strategy, robust financials, and strong product growth, with FIRDAPSE and AGAMREE driving expansion. Patient-centric programs, aggressive business development, and a $700M cash position support ongoing acquisitions and market leadership.
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies
CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals Transcript: BofA Securities CNS Therapeutics Virtual Conference 2025
The conference highlighted a focus on rare disease asset acquisition, lifecycle management, and label expansion for key products. Agamree and Firdapse are central to growth, with robust IP defense and new market opportunities, while capital allocation remains flexible for both buybacks and business development.
Catalyst Pharmaceuticals Transcript: Citi Annual Global Healthcare Conference 2025
The company is executing a buy-and-build strategy in rare diseases, focusing on maximizing growth for Firdapse and Agamree while managing Fycompa's generic impact. Strong clinical data, expanding market opportunities, and a robust cash position support ongoing acquisitions and lifecycle management.
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™
Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution
Catalyst Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
CORAL GABLES, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025
A rare disease-focused commercial organization highlighted strong patient support, robust financials, and a 37% CAGR driven by Firdapse, Agamree, and Fycompa. Strategic use of AI, expanded testing, and updated guidelines are fueling growth, with $689M cash supporting acquisitions and a $200M share buyback.
Catalyst Pharmaceuticals Earnings Call Transcript: Q3 2025
Record Q3 2025 revenue of $148.4M (up 15.3% YoY) driven by strong FIRDAPSE and AGAMREE growth, robust cash flow, and no debt. Full-year revenue guidance raised, with continued momentum expected despite generic pressure on FYCOMPA.
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guida...
Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work
CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference
CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025
The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and c...
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals Transcript: Baird Global Healthcare Conference 2025
A buy-and-build strategy focused on orphan diseases has driven strong growth, with FIRDAPSE and AGAMREE as key assets. FIRDAPSE benefits from new testing and guidelines, targeting major expansion in oncology, while AGAMREE is positioned as a safer DMD steroid with ongoing studies to support label updates. Robust cash reserves and a disciplined acquisition approach support future growth.